SVCM
CYTK icon

Saturn V Capital Management’s Cytokinetics CYTK Stock Holding History

Saturn V Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-348,364
Closed -$16.4M – 23
2024
Q4 		$16.4M Buy
348,364
+17,081
+5% +$887K 6.42% 6
2024
Q3 		$17.5M Buy
331,283
+59,247
+22% +$3.3M 6.25% 7
2024
Q2 		$14.7M Buy
272,036
+8,335
+3% +$503K 5.57% 6
2024
Q1 		$18.5M Sell
263,701
-184,443
-41% -$14.3M 7.41% 3
2023
Q4 		$37.4M Sell
448,144
-47,024
-9% -$1.7M 14.32% 1
2023
Q3 		$14.6M Buy
495,168
+88,943
+22% +$2.96M 6.11% 7
2023
Q2 		$13.3M Buy
406,225
+123,339
+44% +$4.56M 7.35% 4
2023
Q1 		$9.95M Buy
282,886
+85,904
+44% +$3.5M 7.44% 6
2022
Q4 		$7.97M Buy
+196,982
New +$8.48M 6.62% 5

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Saturn V Capital Management's CYTK Position: Q1 2025 in Review

Saturn V Capital Management sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 348,364 shares — an estimated $16.4M sold.

Saturn V Capital Management first reported a position in CYTK in Q4 2022 and held it in 9 quarters. The position peaked at $37.4M in Q4 2023. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • Saturn V Capital Management reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • Saturn V Capital Management sold 348,364 Cytokinetics shares in Q1 2025, an estimated $16.4M.
  • Saturn V Capital Management first reported a position in Cytokinetics in Q4 2022 and held it in 9 quarters.
  • Saturn V Capital Management's Cytokinetics position peaked at $37.4M in Q4 2023.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Saturn V Capital Management's 13F filing for Q1 2025, filed 15 May 2025.